Human Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infections New site ...
Recce is developing a new class of antibiotics to tackle drug-resistant superbugs almost a century after the development of ...
Broad patent coverage spans manufacturing, multiple infection types and flexible delivery methods Strengthens exposure to a major antibiotic market as Recce targets global superbug opportunity Special ...